News | Breast Imaging | March 14, 2017

Hologic Showcases New Breast Cancer Screening and Interventional Solutions at ECR 2017

Company highlighted Affirm prone breast biopsy system, Lateral Arm accessory for upright biopsy

Hologic, ECR 2017, breast cancer screening solutions, Affirm prone biopsy system

The Affirm prone biopsy system. Image courtesy of Hologic.

March 14, 2017 — Hologic Inc. highlighted its portfolio of innovative breast cancer screening and interventional products, including new solutions for biopsy workflow, at the European Congress of Radiology (ECR) in Vienna, Austria, March 1-5. The company also hosted a symposium and several educational workshops throughout the show, giving attendees opportunities to experience screening and interventional products that offer unique patient and user benefits and address workflow challenges. 

Since its European launch at ECR in 2016, the Affirm prone system — what the company calls the first dedicated prone biopsy system that is upgradable to allow 3-D imaging-guided breast biopsies — has experienced positive clinical and patient feedback, with more than 95 percent of patients indicating in a post-procedure survey that the biopsy experience was faster, more comfortable and less painful than expected. The system provides clinicians with added confidence through high-quality imaging, 2-D and 3-D biopsy capability, faster and easier workflow, and seamless, 360-degree access to the breast.  

In addition to the Affirm prone system, Hologic featured a number of other products at ECR, including:

  • The Affirm upright biopsy system for the Selenia Dimensions mammography system;  
  • The new Affirm Lateral Arm accessory for upright biopsy, to improve access to challenging lesion locations and provide additional patient positioning options;
  • Eviva and ATEC breast biopsy systems, designed to conduct minimally invasive biopsy procedures under stereotactic, tomosynthesis, ultrasound or magnetic resonance imaging (MRI) guidance;
  • I-View software for contrast-enhanced digital mammography provides functional imaging information and highly detailed 2-D images that can be combined with Hologic’s 3-D Mammography exam images; 
  • Low-dose 3-D Mammography exams with C-View software, delivering high-end clinical performance to 2-D mammography for all breast types in a faster, more comfortable and lower dose exam; and
  • The Horizon bone densitometry (DXA) system, a single platform for osteoporosis and body composition testing or assessment.

Hologic held the following events at ECR: 

  • Symposium: A Paradigm Shift in Breast Biopsy Clinical Practice: A European Perspective, featuring Dr. Shirley Go, Dr. Gianfranco Scaperrotta and Dr. Alejandro Tejerina;
  • Eight educational workshops on the use and optimization of clinical practice with 3-D Mammography exams and C-View software, the use of I-View software, and new solutions that optimize VABB workflow and patient comfort 

For more information: www.hologic.com

Related Content

News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early...
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
ACR releases 13 new topics and five revised topics to support referring physicians and other providers in making the most appropriate imaging or treatment decisions
News | Radiology Imaging | April 26, 2021
April 26, 2021 — The American College of Radiology (ACR) released an update to its...
The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

News | Breast Imaging | April 23, 2021
April 23, 2021 — The U.S.